Compared to PBMCs from healthy volunteers, treatment of PBMCs from AD patients with COMPOUND 1 (0.1 μM, 24 h) showed a statistically significant increase (p < 0.01) of genes involved in Aβ clearance (i.e., MGAT3 and VDR, four and fivefold increase, respectively) and a decrease in NF-κB and BACE1 (6- and 8-fold-decrease, respectively) (Figure 6). This evidence concerns the gene BACE1 and Alzheimer disease.